Background Randomised controlled trials of passive antibodies as treatment and
prophylaxis for COVID-19 have reported variable efficacy. However, the determinants of …

Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of
coronavirus disease 2019 (COVID-19), has incited a global health crisis. Currently, there are …

Understanding the mechanisms of antibody-mediated neutralization of SARS-CoV-2 is
critical in combating the COVID-19 pandemic. Based on previous reports of antibody …

Background Inborn errors of immunity (IEIs) are considered significant challenges for
children with IEIs, their families, and their medical providers. Infections are the most common …

Abstract Background Since November 2019, the SARS-CoV-2 pandemic has created
challenges for preventing and managing COVID-19 in children and adolescents. Most …

Introduction When Coronavirus Disease-19 (COVID-19) struck the world in December 2019,
initiatives started to investigate the efficacy of convalescent plasma, a readily available …

Abstract Background and Objective During the COVID-19 pandemic, trials on convalescent
plasma (ConvP) were performed without preceding dose-finding studies. This study aimed …

SARS-CoV-2 infection of immunocompromised individuals often leads to prolonged
detection of viral RNA and infectious virus in nasal specimens, presumably due to the lack of …